NCT01369329 2016-12-07A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)Janssen Research & Development, LLCPhase 3 Completed769 enrolled 13 charts